Ba Ria - Vung Tau Eye Hospital
Bà Ria, Ba Ria - Vung Tau, 790000, Vietnam
NCT Number: NCT07064187
The goal of this interventional clinical trial is to learn whether Cationorm can improve symptoms after pterygium surgery. The main question it aims to answer is what is the level of improvement of symptoms after pterygium surgery.
Researchers will compare with other artificial tears (hyaluronic acid, polymers or cellulose derivatives eye drops) arm to see if Cationorm is similar or superior in terms of improvement of symptoms after pterygium surgery.
Participants will
* Take 1 drop Cationorm/artificial tear before and after surgery and during follow up. * Visit for checkups after 7 days
Looking for future studies?
Notify Me35 year–70 year
All sexes
Interventional
Phase 4
Bà Ria, Ba Ria - Vung Tau, 790000, Vietnam
Participants will take:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Cationorm single-dose eye drop is a preservative-free, cationic oil-in-water nano-emulsion.
Other names: Cationic emulsion
Artificial tear eye drops are hyaluronic acid, polymers or cellulose derivatives eye drops
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Time frame: From enrollment to 7 days after surgery
All study outcomes are collected using modified OSDI questionnaire answered by patients before surgery, after surgery and 7 days after surgery.
These outcomes includes the frequency and severity of:
Frequency: Never, Some of the time, Most of the time, All of the time Severity: None, Mild, Moderate, Severe
Nguyen Viet Giap
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03414645
Dry Eye, Dry Eye Syndromes
Palo Alto, California, United States
View Trial DetailsNCT03031327
Jacobs syndrome, Ocular Discomfort
Rome, Italy
View Trial DetailsNCT03035864
Ocular Discomfort
Chieti, Italy
View Trial DetailsNCT03302273
Blepharitis, Dry Eye
Amarillo, Texas, United States
View Trial Details